Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022
Publication type: Journal Article
Publication date: 2022-04-29
scimago Q1
wos Q1
SJR: 9.559
CiteScore: 39.4
Impact factor: 17.3
ISSN: 01492195, 1545861X
PubMed ID:
35482574
General Medicine
Health, Toxicology and Mutagenesis
Epidemiology
Health (social science)
Health Information Management
Abstract
In December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, became predominant in the United States. Subsequently, national COVID-19 case rates peaked at their highest recorded levels.* Traditional methods of disease surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. trends in infection-induced SARS-CoV-2 seroprevalence during September 2021-February 2022, by age group.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
|
|
|
Morbidity and Mortality Weekly Report
10 publications, 3.75%
|
|
|
Open Forum Infectious Diseases
8 publications, 3%
|
|
|
Clinical Infectious Diseases
8 publications, 3%
|
|
|
Vaccines
7 publications, 2.62%
|
|
|
Journal of Infectious Diseases
7 publications, 2.62%
|
|
|
JAMA network open
6 publications, 2.25%
|
|
|
Nature Communications
6 publications, 2.25%
|
|
|
PLoS ONE
6 publications, 2.25%
|
|
|
medRxiv : the preprint server for health sciences
6 publications, 2.25%
|
|
|
Pediatric Infectious Disease Journal
5 publications, 1.87%
|
|
|
Vaccine
5 publications, 1.87%
|
|
|
Journal of Medical Virology
5 publications, 1.87%
|
|
|
Scientific Reports
5 publications, 1.87%
|
|
|
Viruses
4 publications, 1.5%
|
|
|
International Journal of Infectious Diseases
4 publications, 1.5%
|
|
|
Epidemiology and Infection
4 publications, 1.5%
|
|
|
Microbiology spectrum
4 publications, 1.5%
|
|
|
Frontiers in Immunology
3 publications, 1.12%
|
|
|
Emerging Infectious Diseases
3 publications, 1.12%
|
|
|
Journal of Clinical Medicine
3 publications, 1.12%
|
|
|
Influenza and other Respiratory Viruses
3 publications, 1.12%
|
|
|
American Journal of Public Health
3 publications, 1.12%
|
|
|
Journal of Pediatrics
2 publications, 0.75%
|
|
|
The Lancet Infectious Diseases
2 publications, 0.75%
|
|
|
The Lancet Regional Health - Europe
2 publications, 0.75%
|
|
|
The Lancet Regional Health - Americas
2 publications, 0.75%
|
|
|
iScience
2 publications, 0.75%
|
|
|
Journal of the Pediatric Infectious Diseases Society
2 publications, 0.75%
|
|
|
Journal of Medical Ethics
2 publications, 0.75%
|
|
|
2
4
6
8
10
|
Publishers
|
5
10
15
20
25
30
35
40
45
|
|
|
Elsevier
42 publications, 15.73%
|
|
|
Cold Spring Harbor Laboratory
36 publications, 13.48%
|
|
|
Oxford University Press
28 publications, 10.49%
|
|
|
Springer Nature
26 publications, 9.74%
|
|
|
MDPI
19 publications, 7.12%
|
|
|
Wiley
15 publications, 5.62%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
10 publications, 3.75%
|
|
|
American Medical Association (AMA)
9 publications, 3.37%
|
|
|
Taylor & Francis
9 publications, 3.37%
|
|
|
SAGE
8 publications, 3%
|
|
|
Public Library of Science (PLoS)
8 publications, 3%
|
|
|
Centers for Disease Control MMWR Office
7 publications, 2.62%
|
|
|
Centers for Disease Control and Prevention (CDC)
6 publications, 2.25%
|
|
|
American Society for Microbiology
5 publications, 1.87%
|
|
|
Frontiers Media S.A.
4 publications, 1.5%
|
|
|
Cambridge University Press
4 publications, 1.5%
|
|
|
BMJ
4 publications, 1.5%
|
|
|
American Public Health Association
3 publications, 1.12%
|
|
|
American Academy of Pediatrics
3 publications, 1.12%
|
|
|
The American Association of Immunologists
1 publication, 0.37%
|
|
|
Mary Ann Liebert
1 publication, 0.37%
|
|
|
Massachusetts Medical Society
1 publication, 0.37%
|
|
|
The Royal Society
1 publication, 0.37%
|
|
|
European Centre for Disease Control and Prevention (ECDC)
1 publication, 0.37%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.37%
|
|
|
XMLink
1 publication, 0.37%
|
|
|
Eco-Vector LLC
1 publication, 0.37%
|
|
|
IWA Publishing
1 publication, 0.37%
|
|
|
5
10
15
20
25
30
35
40
45
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
267
Total citations:
267
Citations from 2024:
83
(31.09%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Clarke K. E. et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 // Morbidity and Mortality Weekly Report. 2022. Vol. 71. No. 17. pp. 606-608.
GOST all authors (up to 50)
Copy
Clarke K. E., Jones J. C., Deng Y., Nycz E., Lee A., Iachan R., Gundlapalli A. V., Hall A. J., MacNeil A. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 // Morbidity and Mortality Weekly Report. 2022. Vol. 71. No. 17. pp. 606-608.
Cite this
RIS
Copy
TY - JOUR
DO - 10.15585/mmwr.mm7117e3
UR - http://www.cdc.gov/mmwr/volumes/71/wr/mm7117e3.htm?s_cid=mm7117e3_w
TI - Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022
T2 - Morbidity and Mortality Weekly Report
AU - Clarke, Kristie E.N.
AU - Jones, Jefferson C.
AU - Deng, Yangyang
AU - Nycz, Elise
AU - Lee, Adam
AU - Iachan, Ronaldo
AU - Gundlapalli, Adi V
AU - Hall, Aron J.
AU - MacNeil, Adam
PY - 2022
DA - 2022/04/29
PB - Centers for Disease Control MMWR Office
SP - 606-608
IS - 17
VL - 71
PMID - 35482574
SN - 0149-2195
SN - 1545-861X
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Clarke,
author = {Kristie E.N. Clarke and Jefferson C. Jones and Yangyang Deng and Elise Nycz and Adam Lee and Ronaldo Iachan and Adi V Gundlapalli and Aron J. Hall and Adam MacNeil},
title = {Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022},
journal = {Morbidity and Mortality Weekly Report},
year = {2022},
volume = {71},
publisher = {Centers for Disease Control MMWR Office},
month = {apr},
url = {http://www.cdc.gov/mmwr/volumes/71/wr/mm7117e3.htm?s_cid=mm7117e3_w},
number = {17},
pages = {606--608},
doi = {10.15585/mmwr.mm7117e3}
}
Cite this
MLA
Copy
Clarke, Kristie E.N., et al. “Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022.” Morbidity and Mortality Weekly Report, vol. 71, no. 17, Apr. 2022, pp. 606-608. http://www.cdc.gov/mmwr/volumes/71/wr/mm7117e3.htm?s_cid=mm7117e3_w.